Joel Lewis
Net Worth

Last updated:

What is Joel Lewis net worth?

The estimated net worth of Mr. Joel Lewis is at least $7,674,932 as of 23 Dec 2024. He owns shares worth $3,417,616 as insider, has earned $49,616 from insider trading and has received compensation worth at least $4,207,700 in Galectin Therapeutics Inc..

What is the salary of Joel Lewis?

Mr. Joel Lewis salary is $601,100 per year as Pres, Chief Executive Officer & Director in Galectin Therapeutics Inc..

How old is Joel Lewis?

Mr. Joel Lewis is 55 years old, born in 1970.

What stocks does Joel Lewis currently own?

As insider, Mr. Joel Lewis owns shares in one company:

Company Title Shares Price per share Total value
Galectin Therapeutics Inc. (GALT) Pres, Chief Executive Officer & Director 897,012 $3.81 $3,417,616

What does Galectin Therapeutics Inc. do?

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT logo
GALT
Galectin Therapeutics Inc.
$3.81

Joel Lewis insider trading

Galectin Therapeutics Inc.

Mr. Joel Lewis has made only one insider trade between 2018-2024, according to the Form 4 filled with the SEC.

As of 23 Dec 2024 he still owns at least 897,012 units of GALT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 56,000 N/A N/A
Option
Common Stock 56,000 N/A N/A
Sale
Common Stock 56,000 $0.89 $49,616
Purchase
Common Stock 1,000 $3.39 $3,390
Purchase
Common Stock 1,000 $1.52 $1,520
Option
Common Stock 8,000 N/A N/A
Option
Stock option (right to buy) 8,000 N/A N/A
Purchase
Common Stock 12,849 N/A N/A
Purchase
Common Stock Purchase Warrant (right to buy) 42,831 N/A N/A
Purchase
Common Stock 667 N/A N/A
Purchase
Common Stock 1,000 $4.48 $4,484
Purchase
Common Stock 1,000 $4.81 $4,805
Purchase
Common Stock 1,000 $7.06 $7,058

Galectin Therapeutics key executives

Galectin Therapeutics Inc. executives and other stock owners filed with the SEC: